MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

Home・Aktien・SCYNEXIS Inc

SCYNEXIS Inc

Open

0.66 1.54

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.64

Max

0.68

Schlüsselkennzahlen
By Trading Economics
Einkommen	-1.7M -8.6M
Verkäufe	-1M 334K
Gewinnspanne	-2,572.156
Angestellte	28
EBITDA	9.4M -186K

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+446.88% upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	500K 27M
Vorheriger Eröffnungskurs	-0.88
Vorheriger Schlusskurs	0.66

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

0.9307 / 0.9907 Unterstützung & Widerstand

SCYNEXIS Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

21. Jan. 2026, 23:49 UTC

Wichtige Markttreiber

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21. Jan. 2026, 21:12 UTC

Wichtige Markttreiber

Automaker Stocks Rise After Trump Calls Off European Tariffs

21. Jan. 2026, 21:00 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21. Jan. 2026, 20:29 UTC

Wichtige Markttreiber

Chip Makers Gain After Trump Calls Off European Tariffs

21. Jan. 2026, 20:04 UTC

Wichtige Markttreiber

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21. Jan. 2026, 23:48 UTC

Market Talk

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21. Jan. 2026, 23:34 UTC

Market Talk

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21. Jan. 2026, 22:39 UTC

Ergebnisse

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21. Jan. 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

21. Jan. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21. Jan. 2026, 21:35 UTC

Akquisitionen, Fusionen, Übernahmen

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21. Jan. 2026, 21:19 UTC

Ergebnisse

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21. Jan. 2026, 20:45 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Borse Group to Acquire Allfunds for $6.19B

21. Jan. 2026, 20:36 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21. Jan. 2026, 20:31 UTC

Market Talk

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21. Jan. 2026, 20:27 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21. Jan. 2026, 20:27 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21. Jan. 2026, 20:27 UTC

Market Talk

Was It a 'TACO' Event? -- Market Talk

21. Jan. 2026, 20:26 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21. Jan. 2026, 20:23 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21. Jan. 2026, 20:21 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21. Jan. 2026, 20:19 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse Group Agrees to Buy Allfunds

21. Jan. 2026, 20:08 UTC

Ergebnisse

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21. Jan. 2026, 20:03 UTC

Market Talk

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21. Jan. 2026, 19:51 UTC

Market Talk

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21. Jan. 2026, 19:43 UTC

Market Talk

U.S. Ethanol Production Expected to Slip -- Market Talk

21. Jan. 2026, 19:31 UTC

Market Talk

Gold Settles at Fresh All-Time High -- Market Talk

21. Jan. 2026, 19:24 UTC

Ergebnisse

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21. Jan. 2026, 19:10 UTC

Market Talk

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21. Jan. 2026, 18:57 UTC

Market Talk

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Peer-Vergleich

Kursveränderung

SCYNEXIS Inc Prognose

Kursziel

By TipRanks

446.88% Vorteil

12-Monats-Prognose

Durchschnitt 3.5 USD 446.88%

Hoch 4 USD

Tief 3 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für SCYNEXIS Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

Buy

Halten

Sell

Basierend auf 2 Analysten, die in den letzten 3 Monaten Aktienbewertungen für SCYNEXIS Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

0.9307 / 0.9907Unterstützung & Widerstand

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There are no events.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über SCYNEXIS Inc

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.